Clinical Trial Update: A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study evaluating the safety and efficacy of subconjunctival sirolimus for dry eye in the CAE model has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Santen Inc. | Conditions: Dry Eye | Phase 2 | Status: COMPLETED